Merck announced data from its study of the cardiovascular (CV) safety of sitagliptin (Januvia) at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston, MA. The results were also published in the New England Journal of Medicine.
In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), 14,724 patients with type 2 diabetes and established CV disease from 38 countries were randomized to receive sitagliptin or placebo in addition to usual care. The median patient follow-up was three years and the primary composite endpoint was time to first confirmed event of CV-related death, nonfatal myocardial infarction (MI), nonfatal stroke, or hospitalization for unstable angina.
Adding sitagliptin to usual care was not associated with an increased risk of CV events, hospitalization for heart failure, and rates of all-cause mortality. There was also no increased risk of pancreatitis and pancreatic cancer. A slight reduction in eGFR was observed in both treatment groups at month 48 of the study.
For more information call (800) 672-6372 or visit Januvia.com.